entertainment -WSS

entertainment

author：entertainment 2025-10-01 01:00:15 - browse：2

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： The battle over the Brookhaven Landfill on Long Island

WSS

Donald Trump's relentless attacks on special counsel Jack Smith

Vertex non

What we need to know about Arena Bioworks

New guidelines on severe brain injury complicate already difficult decisions

Death of patient in Alzheimer’s trial raises question of possible risks

Colonoscopy at 40? Study finds a possible benefit

entertainment

entertainment

focus

Continuity nursing helped my family in our darkest PICU moments

Medicare drug price negotiation’s day in court

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

United colonoscopy coverage change 'may cost lives,' doctors say

Congressmen charge Covid hearing ‘could have been an email’

ChatGPT in medicine: STAT answers readers' burning questions

Novo Nordisk to expand supply of Wegovy for U.S. patients

At least 13 dead in Texas as scorching temps continue

Cybersecurity threat forces Lurie Children's to take systems offline

explore

Weight bias in eating disorder treatment complicated by new weight loss drugs

Quicker fix for pulse oximeters urged during FDA public meeting

The strategy behind pharma's lawsuits over drug pricing reform

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Quicker fix for pulse oximeters urged during FDA public meeting

Gene therapy has helped boys walk. Can scientists keep it that way?

focus

knowledge

focus

entertainment